Omega-3 Fatty Acids: History and Discovery

For most of medical history, dietary fat was treated as little more than fuel — calories you could swap for sugar or starch. That assumption was overturned by a married pair of scientists in 1929, and then transformed again half a century later when two Danish doctors went to Greenland to ask why the Inuit, on a diet drenched in fat, so rarely seemed to have heart attacks. This page traces that arc honestly: from the bench-top rat studies that first proved some fats are essential, through the famous — and later much-debated — Greenland fieldwork, to the modern era of fish-oil capsules and the large clinical trials that have complicated the simple story. Where the evidence is firm we say so; where an early claim was later questioned, we say that too.

Table of Contents

  1. What the Omega-3 Family Is
  2. When Fat Was Just Fuel
  3. The Burrs and the Birth of "Essential Fatty Acids" (1929–1930)
  4. Naming the Marine Omega-3s: EPA and DHA
  5. Greenland: Bang and Dyerberg in the 1970s
  6. From Observation to Hypothesis: Platelets and Thrombosis
  7. The Omega-6 to Omega-3 Ratio Debate
  8. The Supplement Era and the Trials That Complicated It
  9. Reassessing the Greenland Story
  10. Research Papers and References
  11. Connections

What the Omega-3 Family Is

Before the history, a quick orientation, because the names recur throughout the story. Omega-3 fatty acids are a family of polyunsaturated fats defined by a chemical detail: the first double bond sits three carbons in from the methyl, or "omega," end of the molecule. Three members matter most for human health. Alpha-linolenic acid (ALA) is the short-chain, plant-based omega-3 found in flaxseed, walnuts, and leafy greens. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the longer-chain "marine" omega-3s concentrated in oily fish and the algae those fish ultimately eat.

The reason this distinction runs through the whole history is that the human body handles the two groups very differently. ALA is genuinely essential — we cannot make it and must get it from food — but we convert it into EPA and DHA only inefficiently. That single fact is why, again and again across this story, attention shifted from the plant omega-3 the Burrs first identified toward the marine omega-3s that the Greenland researchers later found circulating in Inuit blood. Keeping ALA, EPA, and DHA straight is the key to following how the science actually unfolded.

Back to Table of Contents

When Fat Was Just Fuel

For the first decades of modern nutrition science, dietary fat had a humble reputation. It was understood as a concentrated energy source — more calories per gram than protein or carbohydrate — and largely interchangeable with those other fuels. The vitamins were the exciting frontier of the 1910s and 1920s; the idea that any particular fat might be indispensable, something the body could not build for itself, was not on most researchers' radar. A well-fed animal, the thinking went, could synthesize whatever fatty material it needed from sugar and protein.

This is the backdrop against which the first real discovery lands, and it is worth pausing on, because it explains why that discovery was so surprising at the time. Nobody was looking for an "essential fat" because the prevailing view held that no such thing existed. The breakthrough did not refine an existing idea — it contradicted a settled assumption, which is part of why it took years to be fully accepted.

Back to Table of Contents

The Burrs and the Birth of "Essential Fatty Acids" (1929–1930)

The foundational discovery belongs to a husband-and-wife team, George O. Burr and Mildred M. Burr, working at the University of Minnesota. (George Burr had earlier trained at Minnesota and worked in Herbert Evans' laboratory at the University of California, Berkeley, before returning to Minnesota's new botany department, where the key experiments were done.) Their method was painstaking: they raised rats on a rigorously purified, fat-free diet — sucrose and casein, with carefully prepared salts and the known vitamins added back — so that the only thing missing was fat itself. The animals developed a distinctive deficiency syndrome: scaly skin, a scaly tail, stunted growth, water loss through the skin, and eventually death.

In their landmark 1929 paper in the Journal of Biological Chemistry, "A New Deficiency Disease Produced by the Rigid Exclusion of Fat from the Diet," the Burrs showed that this was a true nutritional deficiency — and crucially, that saturated fats did not cure it, but the unsaturated fatty acid linoleic acid did. A 1930 follow-up, "On the Nature and Rôle of the Fatty Acids Essential in Nutrition," extended the finding to alpha-linolenic acid — the omega-3 counterpart of linoleic acid. The Burrs coined the term that endures to this day: essential fatty acids.

It is worth being precise about what was, and was not, established here. The Burrs proved that certain fats are dietary necessities, and they identified both the omega-6 parent (linoleic acid) and the omega-3 parent (alpha-linolenic acid). What they did not do — and could not have done with the tools of 1929 — was demonstrate any link between these fats and heart disease. That connection lay nearly fifty years in the future, and it would come not from a laboratory bench but from fieldwork in the Arctic.

Back to Table of Contents

Naming the Marine Omega-3s: EPA and DHA

Between the Burrs' work and the Greenland studies, chemists steadily filled in the omega-3 family tree. The short-chain plant omega-3, alpha-linolenic acid, was already known. Over the middle decades of the twentieth century, the longer-chain marine omega-3s — eicosapentaenoic acid (EPA), a 20-carbon chain, and docosahexaenoic acid (DHA), a 22-carbon chain — were characterized and recognized as the predominant polyunsaturated fats in fish and marine oils. Cod liver oil, it is worth noting, had been used as a folk and then medical remedy since the 1700s and 1800s, long before anyone knew which molecules it contained; its value was later understood to rest partly on vitamins A and D and partly on these very omega-3s.

This chemical groundwork mattered enormously for what came next. When the Greenland researchers later analyzed Inuit blood and food, they were not naming brand-new compounds — they were measuring substances chemistry had already identified. Their contribution was to connect those known molecules to a striking pattern of human health. The molecules were on the shelf, so to speak; the Greenland work supplied the story that made the world care about them.

Back to Table of Contents

Greenland: Bang and Dyerberg in the 1970s

The pivotal chapter opens with two Danish physician-researchers, Hans Olaf Bang and Jørn Dyerberg. They were intrigued by reports that the Inuit (then commonly called Eskimos) of Greenland appeared to have low rates of heart attack despite a diet extraordinarily high in fat and cholesterol — seal, whale, and fish — with very little fruit, vegetable, or fiber. This seemed to defy the diet-heart thinking of the era, which fixated on saturated fat and cholesterol as villains. Beginning with an expedition to Greenland's remote north-west coast in 1970, and returning over the following years, Bang and Dyerberg collected blood and dietary data directly in the field.

Their first major paper appeared in The Lancet in 1971: "Plasma Lipid and Lipoprotein Pattern in Greenlandic West-Coast Eskimos," with Aase Brøndum Nielsen as co-author. Compared with Danish controls, the Inuit had markedly lower plasma triglycerides and a distinctive lipid profile. A 1975 paper in the American Journal of Clinical Nutrition (Dyerberg, Bang, and Hjørne) pinned down the chemistry: the Inuit blood was unusually rich in the marine omega-3s EPA and DHA, and correspondingly low in the omega-6 arachidonic acid — the opposite of the Danish pattern.

Two cautions belong here, in the spirit of honest history. First, what the team rigorously documented was a difference in blood fats and diet, not a carefully measured difference in heart-attack rates — the low cardiovascular mortality was an impression drawn from imperfect regional records, a point that would be challenged decades later (see below). Second, "Eskimo" is the historical term used in these original papers; "Inuit" is the term preferred today, and this page uses it except when naming the studies directly.

Back to Table of Contents

From Observation to Hypothesis: Platelets and Thrombosis

Bang and Dyerberg did not stop at describing the Inuit lipid profile; they proposed a mechanism. Working with British prostaglandin pioneers, they advanced the idea that EPA changes how blood platelets behave — making them less prone to clump together and form the clots that trigger heart attacks and strokes. In a 1978 Lancet paper, "Eicosapentaenoic Acid and Prevention of Thrombosis and Atherosclerosis?", Dyerberg and Bang teamed with Stoffersen, Moncada, and Vane — Sir John Vane and Salvador Moncada being central figures in prostaglandin science, with Vane a future Nobel laureate — to argue that EPA shifts the body toward less-aggregating signaling molecules (a thromboxane, TXA3, that does not clump platelets the way the omega-6-derived TXA2 does).

A 1979 Lancet paper, "Haemostatic Function and Platelet Polyunsaturated Fatty Acids in Eskimos," reported that the Inuit had measurably longer bleeding times and reduced platelet aggregation — consistent with the hypothesis. Note the question mark in the 1978 title: even the authors framed this as a hypothesis to be tested, not a proven fact. That is exactly the right way to read it. The Greenland work was a brilliant, generative observation and mechanism — it pointed research in a productive direction and, by one accounting, helped launch thousands of follow-up studies — but on its own it could not prove that taking omega-3s prevents heart disease in the general population.

Back to Table of Contents

The Omega-6 to Omega-3 Ratio Debate

One enduring idea to emerge from this line of research is the omega-6 to omega-3 ratio. The argument, associated especially with the work of Artemis Simopoulos from the 1980s and 1990s onward, runs roughly as follows: human beings evolved on a diet in which omega-6 and omega-3 fats were roughly balanced, perhaps close to a 1:1 ratio. The modern Western diet, flooded with omega-6-rich seed and vegetable oils and short on marine omega-3s, has pushed that ratio dramatically higher — estimates commonly cited range from about 10:1 up to 20:1 or more. Because omega-6 and omega-3 fats compete for the same enzymes and give rise to signaling molecules with opposing tendencies (broadly, more versus less inflammatory and clot-promoting), proponents argue this lopsided ratio nudges the body toward chronic inflammation and cardiovascular risk.

This framing is intuitive, historically grounded, and genuinely useful for thinking about how diets have shifted — but it remains a debated hypothesis, not a closed case. A substantial body of expert opinion holds that the absolute amounts of each fat matter more than the ratio, and that omega-6 linoleic acid is not the dietary villain the ratio argument can make it seem; several analyses associate higher linoleic acid intake with lower, not higher, heart-disease risk. The honest summary is that nearly everyone agrees Western diets are short on omega-3s, while experts continue to disagree about whether we eat too much omega-6. This page presents the ratio as an influential idea with real evidence on multiple sides, not as settled science.

Back to Table of Contents

The Supplement Era and the Trials That Complicated It

The Greenland findings, amplified by media and industry, helped launch fish oil into one of the world's best-selling supplements. The scientific test of the omega-3 hypothesis, however, came from large randomized controlled trials — and their results have been decidedly mixed, which is the most important and most frequently glossed-over part of this story. An early and encouraging result was GISSI-Prevenzione (1999), an Italian trial in which heart-attack survivors given about 1 gram of EPA+DHA daily showed reduced cardiovascular and sudden-cardiac death. For years this was treated as confirmation.

The picture grew more complicated as larger and more rigorous trials reported. Two major 2018–2019 trials of modest-dose fish oil, ASCEND (in people with diabetes) and VITAL (primary prevention in generally healthy adults), found no significant benefit on their main composite cardiovascular endpoints, though some secondary analyses hinted at reductions in particular outcomes such as heart attacks. Against this, REDUCE-IT (2019) reported a striking ~25% reduction in cardiovascular events — but it used a high dose (4 grams daily) of a purified EPA-only prescription drug (icosapent ethyl) in high-risk patients already on statins, and its results have been the subject of vigorous debate, partly over whether the mineral-oil placebo may have exaggerated the apparent benefit.

The fair reading of this evidence is nuanced rather than triumphant. Over-the-counter, low-dose fish oil has not reliably prevented heart disease in well-designed trials of broad populations; high-dose, purified, prescription EPA may help specific high-risk groups; and eating fish remains sensibly associated with cardiovascular and other benefits in observational studies. The half-century journey from a Greenland petri dish of Arctic blood to a shelf full of capsules is a case study in how a compelling early observation can outrun, and then be partly checked by, the harder evidence that follows.

Back to Table of Contents

Reassessing the Greenland Story

No honest history of omega-3s can end without revisiting its own founding legend. In 2014, J. George Fodor and colleagues published a critical review in the Canadian Journal of Cardiology, pointedly titled "'Fishing' for the Origins of the 'Eskimos and Heart Disease' Story: Facts or Wishful Thinking?" Reviewing the literature, they argued that Bang and Dyerberg's original studies never actually measured the rate of coronary artery disease in the Greenland Inuit — the famous "low heart-attack rate" rested on incomplete and unreliable regional health records. By some analyses, Inuit populations of that era in fact had cardiovascular disease comparable to other groups, higher stroke mortality, roughly double the overall mortality, and a shorter life expectancy than Danes.

This reassessment does not erase the importance of the Greenland work, and it should not be read as "omega-3s were debunked." The biochemistry the team uncovered — the genuinely unusual EPA- and DHA-rich blood profile, and the real effects on platelets — stands. What the critique punctures is the over-tidy folk version: the claim that the Inuit's marine diet had been proven to protect their hearts. That specific causal story was a hypothesis dressed up over time as established fact, exactly the kind of confirmation bias the 2014 review names.

The honest conclusion is therefore a layered one. The Burrs proved some fats are essential — firmly established. The marine omega-3s EPA and DHA are real, important molecules whose biology Bang and Dyerberg illuminated — firmly established. That omega-3 supplements broadly prevent heart attacks in the general population — not established, and largely not borne out by the strongest trials. Holding those three statements together, without collapsing them into a single slogan, is what it means to tell this history accurately.

Back to Table of Contents

Research Papers and References

The list below gathers the primary papers behind the omega-3 story — the Burrs' foundational work, the Bang and Dyerberg Greenland series, the major clinical trials, and the later critical reassessment — together with reputable reviews and authoritative resources. Author names, titles, and journals are given as plain text; only the stable DOI, PMID, or topic-search link is hyperlinked, and each opens in a new tab. Where a paper predates digital identifiers, a PubMed or archival link is provided instead.

  1. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. Journal of Biological Chemistry. 1929;82(2):345-367. — jbc.org — full text
  2. Burr GO, Burr MM. On the nature and rôle of the fatty acids essential in nutrition. Journal of Biological Chemistry. 1930;86(2):587-621. — jbc.org — full text
  3. Spector AA, Kim HY. Discovery of essential fatty acids. Journal of Lipid Research. 2015;56(1):11-21. — doi:10.1194/jlr.R055095 · PMID: 25339684
  4. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971;1(7710):1143-1145. — doi:10.1016/S0140-6736(71)91658-8 · PMID: 4102857
  5. Dyerberg J, Bang HO, Hjørne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. American Journal of Clinical Nutrition. 1975;28(9):958-966. — doi:10.1093/ajcn/28.9.958 · PMID: 1163480
  6. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978;2(8081):117-119. — doi:10.1016/S0140-6736(78)91505-2 · PMID: 78322
  7. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 1979;2(8140):433-435. — doi:10.1016/S0140-6736(79)91490-9 · PMID: 89498
  8. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447-455. — doi:10.1016/S0140-6736(99)07072-5 · PMID: 10465168
  9. Fodor JG, Helis E, Yazdekhasti N, Vohnout B. "Fishing" for the origins of the "Eskimos and heart disease" story: facts or wishful thinking? Canadian Journal of Cardiology. 2014;30(8):864-868. — doi:10.1016/j.cjca.2014.04.007 · PMID: 25064579
  10. Bhatt DL, Steg PG, Miller M, et al (REDUCE-IT Investigators). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22. — doi:10.1056/NEJMoa1812792 · PMID: 30415628
  11. Manson JE, Cook NR, Lee IM, et al (VITAL Research Group). Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine. 2019;380(1):23-32. — doi:10.1056/NEJMoa1811403 · PMID: 30415637
  12. Simopoulos AP — evolutionary aspects of the omega-6/omega-3 ratio — PubMed: Simopoulos omega-6/omega-3 ratio (evolutionary aspects)

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents